Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

"K-NK002 will be administered intravenous (IV) on Day -2, Day +7 and Day +28.~Part One (Safety run-in):~An initial safety run-in to confirm the starting dose, and safety and tolerability of K-NK002;~* Dose cohort 1 will include 3 patients who will receive a dose of K-NK002 at 1 x 10E7 NK cells per kg.~* Dose cohort 2 will include 3 patients who will receive K-NK002 at 1 x 10E8 NK cells per kg.~Part Two (Open Enrollment):~Enrollment into the second part of the study (Open Enrollment) can begin following Part One, confirmation of dose and safety."

"From Day -7 to Day -3:~* Melphalan: 140 mg/m2 (100mg/m2 in patients ≥ 60) on Day -7.~* Fludarabine: 40 mg/m2 daily for 4 doses starting on days -7.~* TBI: 2 Gy on Day -3."

Bone marrow is the only allowed graft source for patients enrolled in this clinical trial